In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Dexmedetomidine In in vivo Murine Traumatic Brain Injury Model

    Final Number:
    428

    Authors:
    Todd Douglas Vogel MD; Charles Glen Kulwin MD; Xiang Gao PhD; Jinhui Chen MD, PhD

    Study Design:
    Laboratory Investigation

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2014 Annual Meeting

    Introduction: Traumatic brain injury has been shown to involve secondary injury pathways including autonomic dysregulation, ischemia, and excitotoxicity leading to neuronal death. Dexmedetomidine is an alpha-2 agonist that has demonstrated neuroprotection in animal models for ischemia and excitotoxicity. There have been no published reports of dexmedetomidine's effectiveness in neuroprotection following traumatic brain injury.

    Methods: Controlled cortical impact through a pneumatic device was used to create a moderate head injury in 8 week-old mice. The mice were randomized to receive either saline or dexmedetomidine at 1ug/kg, 10ug/kg, or 100ug/kg doses at 1 hour and 12 hours after injury. Mice were sacrificed at 24 hours after injury. Histopathological analysis was carried out using Fluoro Jade-B and cresyl violet staining. Fluoro Jade-B staining was used to mark neuronal death in the dentate gyrus. Cresyl violet staining allowed for quantification of ischemic damage to the cortex.

    Results: There was significantly less neuronal death at 1ug/kg and 100ug/kg dexmedetomidine compared to saline (p < 0.05). There was significantly less ischemic damage in the cortex at 10ug/kg, but not at 1ug/kg or 100ug/kg doses (p < 0.05).

    Conclusions: Dexmedetomidine demonstrated neuroprotection in a in vivo murine model for TBI. Dexmedetomidine deserves further research to determine if these results can be duplicated in other animal models and possibly applied to humans.

    Patient Care: Dexmedetomidine is a FDA-approved sedative that has a histopathological neuroprotective effect in multiple ischemic and excitotoxic animal models and now in a TBI animal model. Dexmedetomidine deserves further research to see if this neuroprotection potentially carries over to improved clinical outcomes in humans.

    Learning Objectives: At the end of the presentation, participants will understand the potential role for dexmedetomidine in traumatic brain injury.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy